Ulcerative Colitis

Comprising TV, radio, and print PSAs, the campaign includes a spot produced especially for rock radio, which features Pearl Jam's lead guitarist, Mike McCready, who has Crohn's disease.

This is the third PSA campaign funded by the Mankoff Family Foundation of Dallas, which pledged $1 million to CCFA in 2004.

"We're succeeding in building awareness of IBD.

Last year's PSA campaign achieved great results," said Jeffrey Mankoff, who is a past president of CCFA's North Texas Chapter.

"For the 2005 campaign, stations contributed more than $11 million worth of airtime, and audience impressions exceeded 804 million.

We believe that 'Symptoms' will do even better.

Our family is proud to support this important effort." Two national Omnibus studies, conducted by GfK NOP in 2003 and 2005, indicated that awareness of CCFA advertising had nearly doubled since the first campaign was released in 2003.

Moreover, according to Nielsen Media Research's 2005 year-end ranking report, CCFA's 2005 television PSA ranked in the top 10 percent of all PSAs tracked over the past year.

"All too often, people go undiagnosed for years, because they've never heard of Crohn's and colitis or because they're too embarrassed to talk about their symptoms," said Mark Goldman,...

Antibe's development strategy is to improve existing drugs by incorporating immunomodulatory components into their molecular structure, generating new, fully patent-protectable chemical entities with predictable toxicity and effectiveness profiles.

This approach is underpinned by a unique biotechnology platform, enabling the efficient development of improved versions of a range of drugs presently on the market.

The Company's lead drug is a derivative of mesalamine (5-aminosalicylic acid).

Mr.

Daniel Legault, President and CEO of Antibe Therapeutics commented, "This award from AHFMR represents strong third party validation of ATB-429, and of our drug development program as a whole.

We look forward to initiating our clinical trials, which are designed to rapidly establish proof-of-concept of this product in humans.

We are pleased that the AHFMR has chosen to support this innovative drug development program." About AHFMR: AHFMR's Technology Commercialization (TC) program assists Alberta innovators with the transfer of new ideas and scientific findings into successful commercial health-related products and services.

Since 1985, the TC program has supported over 240 people and projects for over $20 million.

About Antibe: Antibe Therapeutics is a privately held, early stage drug development company with offices in Calgary and Toronto, and with affiliate laboratories in the USA, United King...